Insmed Incorporated announced the appointment of two new independent directors to its Board of Directors, effective October 19, 2026. The new appointees are Paul Hudson and Utpal Koppikar.
Paul Hudson has been appointed as a Class II director and will serve on the Board's Compensation Committee. Mr. Hudson brings more than three decades of senior executive leadership experience. He most recently served as Chief Executive Officer of Sanofi S.A. from September 2019 through February 2026, where he led a sweeping transformation of the organization. Prior to Sanofi, he served as CEO of Novartis Pharmaceuticals from 2016 to 2019 and held senior operational and commercial leadership positions at AstraZeneca, including President of AstraZeneca United States.
Utpal Koppikar has been appointed as a Class I director and will serve on the Board's Audit Committee. Mr. Koppikar is a seasoned biopharma finance executive. He has served as Chief Financial Officer of Verily Health Inc. since April 2023. Previously, he served as Executive Vice President and CFO at Atara Biotherapeutics from 2018 to 2023 and held senior financial leadership positions at Gilead Sciences and Amgen.
In connection with their service on the Board, each director will receive an annual cash retainer of $65,000, prorated in the current year. Additionally, Mr. Hudson will receive an additional annual cash retainer of $12,500 for his role on the Compensation Committee, and Mr. Koppikar will receive an additional annual cash retainer of $12,500 for his role on the Audit Committee. Both retainers are also prorated based on the date of appointment.
Furthermore, each director will receive a grant of restricted stock units with a grant date fair value of approximately $585,000. The RSUs will vest in equal parts on the first three one-year anniversaries of the grant date, provided the directors remain on the Board on each vesting date.
